commercialize

CSL - Science Center Research Acceleration Initiative

Working together to identify and commercialize promising new technologies at research and academic institutions across the region

APPLICATION DEADLINE EXTENDED to April 27, 2020

FUNDING: up to US $400,000 per project

 

CSL Behring is a leading global biotechnology company that develops and delivers innovative biotherapies to help people living with life threatening medical conditions live full lives. CSL has partnered with the Science Center, a nonprofit institution that is dedicated to identifying and nurturing promising technology for over half a century, to build the CSL-Science Center Research Acceleration Initiative (CSL-Sc RAI). The initiative is designed to source research and fast-track discovery through partnerships between CSL and leading life sciences research institutions. Selected projects receive funding and access to industry resources for scientists working on novel technologies in CSL’s therapeutic areas.

 

funding mechanism

 

The Research Acceleration Initiative is a partnership, with university investigators, intended to further develop promising new technologies.  The process begins with the submission of a preproposal by interested investigators.  These applications should include a non-confidential description of the technology, the proposed market and a general research plan to increase the idea’s commercial readiness.

 

Preproposals will be reviewed within CSL, and a number of finalists will receive invitations to present in person a more detailed description of the opportunity.

 

Selected awardees will then be engaged by CSL with two aims.  The first will be to establish a final research plan in conjunction with CSL scientists and bringing to bear CSL resources that might not be independently available to the research team.  The second will be to begin negotiations with the hosting technology transfer office to formalize the relationship via a research and option agreement.

 

Once the research and option agreement has been executed the project will commence.

 

The Initiative will fund up to three proposals in 2020. Successful applicants will receive up to $200,000 per year for up to two years (maximum $400,000 funding) to accelerate translation of their research. Because the funding will be in the form of research partnerships, interested investigators must engage their  institution’s technology transfer office prior to submitting an application.

 

Pre-proposal applications will be accepted through 5 p.m. on April 27, 2020.

 

The CSL – Science Center Research Acceleration Initiative seeks innovations that address CSL Therapeutic and Focus areas, and that are amenable to or include a listed Modality below:

Therapeutic areas

(Emphasis on rare disease)

  • Immunology
  • Neurology
  • Haematology
  • Thrombosis
  • Transplant
  • Respiratory
  • Cardiovascular / Metabolic

focus areas

  • Novel drug targets
  • Novel therapeutic candidates
  • Novel strategies for treating disease

 

modalities

  • Antibodies
  • Protein therapeutics
  • Gene therapies
  • Cell therapies
  • Small molecules not of interest

How to apply

 

The CSL-Science Center Research Acceleration Initiative seeks promising new technologies relevant to CSL Behring’s mission of developing and delivering innovative biotherapies and to build new partnerships between CSL and leading research institutions.

 

The process has four stages:

  • call for pre-proposals
  • face-to-face presentation and discussion of high-interest technologies
  • partnering and licensing negotiation
  • two-year R&D period

 

Up to $400,000 over two years is available per technology.

 

Applicant technologies should have clinical application in immunology, neurology, hematology and thrombosis, transplantation, respiratory illness, or cardiovascular/metabolic diseases. CSL has interest in novel drug targets, therapeutics, and strategies for treating disease. Modalities of interest include antibodies and other protein therapeutics, and cell- and gene therapies. Small molecules are not of interest.

 

Applicants are reminded that the initial pre-proposal should not be regarded as confidential. Previously undisclosed or unpublished intellectual property should not be shared in this pre-proposal.

 

DETAILED INSTRUCTIONS

 

1) RESEARCH AND DEVELOPMENT PRE-PROPOSAL

The pre-proposal should be in the form of a 3-page PDF document, with single-spaced, 11-point font and 1 inch margins. Figures and illustrations are encouraged. Each application must address the following topics. Applicants should use their judgement as to how much detail is required for each element. Each section should have a written header.

 

Header 1: "Technology and Key Supporting Data"

  • What is the proposed innovation?
  • What would the final envision product be?
  • What data have been collected supporting a commercial opportunity? (Provide key figures or tables as needed)
  • What is the next step in advancing the technology?

Header 2: "Anticipated Market and Competing Technologies"

  • What illness or clinical need does the technology address?
  • What is the magnitude (e.g., number of patients affected) of that problem nationally? Globally?
  • What is the current standard of care?
  • What existing product would the new technology displace?

Header 3: "The Team"

  • Who is leading project? What are their qualifications?
  • Are there other key project participants the reviewers should be aware of?
  • Are there key participants involved who are not employed by the host institution?
  • Who is the project lead within the Technology Transfer Office? What is their experience with university-industry partnership?

Header 4: "Proposed Experimental Plan"

  • What experiments or business development activities are planned over the two-year program?
  • Why is the proposed work essential for commercial, rather than research, development of the idea?
  • Provide a quarterly, two-year milestone timeline covering the proposed work
  • Are there particular resources or expertise that the project team needs?

Header 5: "Use of Funds"

  • Provide a high level projection of the use of funds (e.g., salary, supplies, equipment, clinical costs, third party contracting, or travel).

 

2) TECHNOLOGY TRANSFER OFFICE LETTER OF ENDORSEMENT

Each submission must be accompanied by a letter of support from an officer of the host institution’s Technology Transfer Office. Specifically acknowledge in the letter:

  • A listing of the relevant intellectual property, including any background or enabling intellectual property, including stage of IP applications. When possible include USPTO numbers. Jointly held, optioned, or licensed technology should be acknowledged as such.
  • A statement that, in the event the technology is selected for funding, the scientific and technology transfer team will work with the CSL team to finalize the scientific approach;
  • A statement that, in the event the technology is selected for funding, the host university will work towards an option or licensing agreement with a target close no later than December 31, 2020.

TIMELINE AND INFORMATION

March 2, 2020              Opening day for pre-proposal submissions

April 27, 2020               Deadline for receipt of pre-proposal submissions

June 25, 2020                Finalist applicants present research proposals at Science Center to CSL

July 30, 2020                 Finalist applicants selected for funding

For questions regarding the initiative, please email RAI.US@cslbehring.com

 

For all other questions regarding formatting of your application or the application process, please email research@sciencecenter.org

Check back soon for frequently asked questions! 

 

Why collaborate with CSL? 

 

Global capabilities on your doorstep

 

Work with one of the world's leading biotech companies

 

Funding for successful proposals

 

Access to commercial R&D, clinical, intellectual property, marketing and manufacturing expertise

 

Accelerate Translation of your research to deliver new therapies to patients

 

Sharon Ross

Program Manager

215-966-6142